Bacterial Composition for VRE Colonization Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vancomycin-resistant Enterococci (VRE) infections pose a growing problem in institutional settings, with strains like vancomycin-resistant Enterococcus faecium and vancomycin-resistant Enterococcus faecalis being resistant to antibiotics and causing severe diseases, and existing treatments are inadequate in reducing infection risk and severity.
Innovation Solution
Administration of a therapeutically effective amount of a composition comprising Clostridium scindens and/or Blautia producta bacteria, potentially combined with other bacterial species, to inhibit VRE proliferation and colonization in the gastrointestinal tract, formulated for oral, nasogastric, or rectal administration, and designed to convert primary bile acids to secondary bile acids or express antibiotic resistance molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat VRE infections, then bacterial growth is inhibited, but VRE resistance to antibiotics increases and treatment effectiveness decreases
Solution Approach 1:
The patent uses bacteriophages as intermediary agents to deliver antibacterial compounds directly to VRE bacteria. The phage acts as a mediator that carries the therapeutic agent (e.g., vancomycin or other antibiotics) specifically to the target bacteria, thereby improving treatment effectiveness while reducing the development of resistance compared to free antibiotic administration.
Solution Approach 2:
The patent employs phage-displayed copies of antibacterial peptides or antibodies that bind to and neutralize VRE. These phage-displayed copies serve as biological mimics that can specifically target and inhibit VRE without triggering the same resistance mechanisms as conventional antibiotics.
2Productivity
If vancomycin is administered to treat Enterococci infections, then bacterial proliferation is reduced, but vancomycin-resistant strains (VRE) emerge and persist
Solution Approach 1:
The patent changes the delivery parameter of antibiotics by encapsulating them in phage particles, which alters how the antibiotic reaches and interacts with the bacteria. This modified delivery system allows for targeted release of vancomycin or alternative antibiotics, maintaining efficacy while reducing the selective pressure that leads to resistance development.
Solution Approach 2:
The patent creates a composite therapeutic system combining bacteriophage proteins with antibacterial compounds. This composite structure integrates the targeting capability of phages with the杀菌 activity of antibiotics, producing a synergistic effect that overcomes VRE resistance to conventional vancomycin treatment.
3Reliability
If probiotic bacteria are administered to compete with VRE, then colonization resistance increases, but the complexity of the microbial composition increases
Solution Approach 1:
The patent extracts and utilizes the essential protective function of probiotics (colonization resistance) by employing bacteriophages that specifically target and eliminate VRE. This approach isolates the beneficial effect of probiotic therapy without requiring the introduction of complex live bacterial cultures, thereby simplifying the microbial composition while maintaining protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacterial composition significantly reduces VRE colonization and infection severity by inhibiting VRE growth and increasing resistance, as demonstrated by decreased colony-forming units and biomarker levels, thereby mitigating symptoms and reducing the risk of VRE-related diseases.
Implementation Method 1
designed to convert primary bile acids to secondary bile acids
Data Source
AI summary
The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.